SCHEMBL4676484

SCHEMBL4676484

O=C(Cc1ccc(Cc2ccc(F)c(F)c2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.35
KDM5B Q9UGL1 3/20 0.35
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MAPT P10636 1/20 0.32
QPCTL Q9NXS2 1/20 0.31
PTGER1 P34995 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
PARP1 P09874 3/20 0.31
MPO P05164 1/20 0.31
METAP2 P50579 1/20 0.31
HTT P42858 1/20 0.30
MAPK8 P45983 1/20 0.30
FYN P06241 1/20 0.30
CACNA1G O43497 1/20 0.30
CACNA1H O95180 1/20 0.30
CACNA1I Q9P0X4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221462 0.88 CYP1A2 (0.35) MAPTPARP1HTT
Hydrochloric Acid SCHEMBL6853681 0.87 CYP1A2 (0.34) MAPTPARP1HTT
SCHEMBL4671810 0.87 HCAR2 (0.42) KDM5AKDM5BMAOAMAOBMAPT
SCHEMBL4672900 0.86 HTT (0.33) PTGER1HTT
SCHEMBL4678602 0.85 SMN1; SMN2 (0.38) MAPTPTGER1HTT
SCHEMBL4672217 0.84 MPO (0.32) PTGER1MPOMAPK8
SCHEMBL4672875 0.84 ALDH1A1 (0.40) MAPTPTGER1HTT
SCHEMBL4676639 0.84 HTT (0.31) HTT
SCHEMBL4678966 0.83 PTGER1 (0.35) PTGER1PARP1
SCHEMBL4677799 0.83 SRD5A2 (0.34) KDM5AKDM5BMAPTKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM5A 1534/4885KDM5B 1480/4885MAOA 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.